Dr. med. Urs Hess
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel) 2021; 13
07.02.2021Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
07.02.2021Cancers (Basel) 2021; 13
Ossenkoppele Gert, Pabst Thomas, Oosterveld Margriet, Obbergh Florence van, Nijziel Marten, Moors Ine, Kooy Marinus van Marwijk, Maertens Johan, Loosdrecht Arjan van de, Legdeur Marie-Cecile, Poel Marjolein van der, Sinnige Harm, Spertini Olivier, Norden Yvette van, Stussi Georg, Westerweel Peter, Weerdt Okke de, Vellenga Edo, Vekemans Marie-Christiane, Velden Walter van der, Tick Lidwine, Terpstra Wim, Lammeren-Venema Danielle van, Kuball Jurgen, Deeren Dries, Chalandon Yves, Brouwer Rolf, Breems Dimitri, Borne Peter von dem, Biemond Bart, Bargetzi Mario, Manz Markus, Löwenberg Bob, Efthymiou Anna, Gjertsen Bjørn-Tore, Graux Carlos, Klift Marjolein van der, Klein Saskia, Jongen-Lavrencic Mojca, Jie Asiong, Jaspers Aurelie, Hoogendoorn Mels, Hess Urs, Heim Dominik, Gregor Michael, Janssen Jeroen
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 2020; 4:3699-3707.
11.08.2020Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
11.08.2020Blood Adv 2020; 4:3699-3707
Benz Rudolf, O'Meara Stern Alix, Cantoni Nathan, Bargetzi Mario, Bianchi-Papina Elena, Rossi Davide, Passweg Jakob, Lohri Andreas, Berardi Simona, Feller Anita, Rauch Daniel, Blum Sabine, Mey Ulrich, Arn Kornelius, Andres Martin, Pabst Thomas, Baumann Michael, Novak Urban, Hitz Felicitas, Hess Urs, Zenhaeusern Reinhard, Chalandon Yves, Stussi Georg
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. Swiss Med Wkly 2018; 148:w14589.
01.03.2018Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
01.03.2018Swiss Med Wkly 2018; 148:w14589
Passweg Jakob R, Masouridi-Levrat Stavroula, Müller Antonia, Nair Gayathri, Pabst Thomas, Renner Christoph, Schmidt Adrian, Stussi Georg, Nicoloso de Faveri Grazia, Schanz Urs, Leibundgut Kurt, Hess Urs, Heim Dominik, Baldomero Helen, Ansari Marc, Baerlocher Gabriela M, Bargetzi Mario, Chalandon Yves, Duchosal Michel A, Gerull Sabine, Güngör Tayfun, Halter Jörg P, For The Swiss Blood Stem Cell Transplantation Group Sbst
Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
Schnegg-Kaufmann A, Bonadies N, Arndt V, Stussi G, Passweg J, Chalandon Y, Spertini O, Hess U, Bargetzi M, Efthymiou A, Gregor M, Manz M, Rovó A, Baldomero H, Feller A, NICER Working Group. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiol 2017; 52:55-62.
07.12.2017Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
07.12.2017Cancer Epidemiol 2017; 52:55-62
Schnegg-Kaufmann Annatina, Bonadies Nicolas, Arndt Volker, Stussi Georg, Passweg Jakob R, Chalandon Yves, Spertini Olivier, Hess Urs, Bargetzi Mario, Efthymiou Anna, Gregor Michael, Manz Markus G, Rovó Alicia, Baldomero Helen, Feller Anita, NICER Working Group
Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
Meissner J, Montoto S, Samaras P, Robinson S, Pioltelli P, Pabst T, Mohty M, Ludwig H, Hess U, Finke J, Delage J, Cornelissen J, Abecasis M, Laboure G, Kanfer E, Boumendil A, Dietrich S, Finel H, Dreger P. Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. Bone Marrow Transplant 2016; 52:650-652.
19.12.2016Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
19.12.2016Bone Marrow Transplant 2016; 52:650-652
Meissner J, Montoto S, Samaras P, Robinson S, Pioltelli P, Pabst T, Mohty M, Ludwig H, Hess Urs, Finke J, Delage J, Cornelissen J, Abecasis M, Laboure G, Kanfer E, Boumendil A, Dietrich S, Finel H, Dreger P
Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse
Gössi F, Schardt J, Bargetzi M, Berthold D, Hess U, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant 2016; 52:334-336.
28.11.2016Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse
28.11.2016Bone Marrow Transplant 2016; 52:334-336
Gössi F, Schardt J, Bargetzi M, Berthold D, Hess Urs, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T
Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. Nutrition 2016; 35:43-50.
15.10.2016Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
15.10.2016Nutrition 2016; 35:43-50
Baumgartner Annic, Mueller Beat, Stanga Zeno, Hess Urs, Duchosal Michel A, Pabst Thomas, Wannesson Luciano, Limonta Alessandro, Pichard Claude, Chalandon Yves, Samaras Panagiotis, Schanz Urs, Passweg Jakob, Medinger Micheal, Zueger Noemi, Bargetzi Annika, Bargetzi Mario, Schuetz Philipp
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Maury S, Braun T, Marolleau J, Cahn J, Chalandon Y, Lhéritier V, Beldjord K, Béné M, Ifrah N, Dombret H, Pignon J, Vey N, Hess U, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med 2016; 375:1044-53.
15.09.2016Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
15.09.2016N Engl J Med 2016; 375:1044-53
Maury Sébastien, Braun Thorsten, Marolleau Jean-Pierre, Cahn Jean-Yves, Chalandon Yves, Lhéritier Véronique, Beldjord Kheira, Béné Marie C, Ifrah Norbert, Dombret Hervé, Pignon Jean-Michel, Vey Norbert, Hess Urs, Chevret Sylvie, Thomas Xavier, Heim Dominik, Leguay Thibaut, Huguet Françoise, Chevallier Patrice, Hunault Mathilde, Boissel Nicolas, Escoffre-Barbe Martine
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
21.02.2015Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
21.02.2015Swiss Med Wkly 2015; 145:w14100
Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
Terwijn M, Graux C, Bargetzi M, Legdeur M, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck L, Gratama J, Oussoren Y, Scholten W, Slomp J, Snel A, Vekemans M, Löwenberg B, Ossenkoppele G, Wijermans P, van Gelder M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T, Maertens J, Boeckx N, de Greef G, Valk P, Preijers F, Huijgens P, Dräger A, Schanz U, Jongen-Lavrecic M, Biemond B, Passweg J, Schuurhuis G. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31:3889-97.
23.09.2013High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
23.09.2013J Clin Oncol 2013; 31:3889-97
Terwijn Monique, Graux Carlos, Bargetzi Mario, Legdeur Marie-Cecile, Kuball Jurgen, de Weerdt Okke, Chalandon Yves, Hess Urs, Verdonck Leo F, Gratama Jan W, Oussoren Yvonne J M, Scholten Willemijn J, Slomp Jennita, Snel Alexander N, Vekemans Marie-Christiane, Löwenberg Bob, Ossenkoppele Gert J, Wijermans Pierre, van Gelder Michel, van Putten Wim L J, Kelder Angèle, van der Velden Vincent H J, Brooimans Rik A, Pabst Thomas, Maertens Johan, Boeckx Nancy, de Greef Georgine E, Valk Peter J M, Preijers Frank W M B, Huijgens Peter C, Dräger Angelika M, Schanz Urs, Jongen-Lavrecic Mojca, Biemond Bart J, Passweg Jakob R, Schuurhuis Gerrit J
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries
Passweg J, Schanz U, Stussi G, Stern M, Renner C, Pabst T, Ozsahin H, de Faveri G, Leibundgut K, Hess U, Güngör T, Gratwohl A, Duchosal M, Chalandon Y, Bucher C, Bargetzi M, Baldomero H, SBST (Swiss Blood Stem Cell Transplantation Group). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Med Wkly 2013; 143:w13757.
22.02.2013Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries
22.02.2013Swiss Med Wkly 2013; 143:w13757
Passweg Jakob R, Schanz Urs, Stussi Georg, Stern Martin, Renner Christoph, Pabst Thomas, Ozsahin Hulya, de Faveri Grazia Nicoloso, Leibundgut Kurt, Hess Urs, Güngör Tayfun, Gratwohl Alois, Duchosal Michel A, Chalandon Yves, Bucher Christoph, Bargetzi Mario, Baldomero Helen, SBST (Swiss Blood Stem Cell Transplantation Group)
Leukämie muss kein Todesurteil mehr sein
Hess U. Leukämie muss kein Todesurteil mehr sein. Schweizer Zeitschrift für Onkologie 2013; 2/2013
01.02.2013Leukämie muss kein Todesurteil mehr sein
01.02.2013Schweizer Zeitschrift für Onkologie 2013; 2/2013
Hess Urs
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2012; 49:290-6.
08.10.2012A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
08.10.2012Eur J Cancer 2012; 49:290-6
Gallerani Elisa, D'Incalci Maurizio, Sala Federica, Cereda Roberta, Marsoni Silvia, de Braud Filippo, Driessen Christoph, Böhm Steffen, Martinelli Giovanni, Delmonte Angelo, Hess Urs, Noberasco Cristina, Marangon Elena, Brunelli Dario, Zucchetti Massimo, Sessa Cristiana
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma 2012; 54:36-40.
09.07.2012Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
09.07.2012Leuk Lymphoma 2012; 54:36-40
Wannesson Luciano, Samaras Panagiotis, Renner Christoph, Pabst Thomas, Lerch Erika, Hess Urs, Heim Dominik, Cerutti Alessandra, Cairoli Anne, Bargetzi Mario, Zucca Emanuele
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
09.08.2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
09.08.2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
Current multiple myeloma treatment strategies with novel agents: a European perspective
Ludwig H, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Hess U, Harousseau J, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15:6-25.
19.01.2010Current multiple myeloma treatment strategies with novel agents: a European perspective
19.01.2010Oncologist 2010; 15:6-25
Ludwig Heinz, Ketterer Nicolas, Kropff Martin, Mendeleeva Larisa, Morgan Gareth, Palumbo Antonio, Plesner Torben, San Miguel Jesús, Shpilberg Ofer, Sondergeld Pia, Sonneveld Pieter, Hess Urs, Harousseau Jean-Luc, Beksac Meral, Bladé Joan, Boccadoro Mario, Cavenagh Jamie, Cavo Michele, Dimopoulos Meletios, Drach Johannes, Einsele Hermann, Facon Thierry, Goldschmidt Hartmut, Zweegman Sonja
Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4484.
01.01.2010Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
01.01.2010J Clin Oncol 2010; 28:4480-4484
Martinelli G, Zucca E, Dietrich P Y, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess Urs, Cerny Thomas, Utiger U, Schmitz S F, Ghielmini M
Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess U, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leukemia & lymphoma 2009:1-11.
04.08.2009Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
04.08.2009Leukemia & lymphoma 2009:1-11
Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess Urs, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S-F Hsu, Tobler A
Grosse Behandlungsfortschritte beim Myelom - Trend zeigt Richtung risikoadaptierte Therapie
Hess U. Grosse Behandlungsfortschritte beim Myelom - Trend zeigt Richtung risikoadaptierte Therapie. Onkologie 2009; 2:22-25.
01.01.2009Grosse Behandlungsfortschritte beim Myelom - Trend zeigt Richtung risikoadaptierte Therapie
01.01.2009Onkologie 2009; 2:22-25
Hess Urs
Viel Bewegung in der Therapie der Myelodysplastischen Syndrome
Hess U. Viel Bewegung in der Therapie der Myelodysplastischen Syndrome. Leading Opinions Hämatologie / Onkologie 2009; 1:52-55.
01.01.2009Viel Bewegung in der Therapie der Myelodysplastischen Syndrome
01.01.2009Leading Opinions Hämatologie / Onkologie 2009; 1:52-55
Hess Urs